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Abstract: Prostate-specific antigen (PSA) is the main biomarker for the screening of prostate cancer
(PCa), which has a high sensibility (higher than 80%) that is negatively offset by its poor specificity
(only 30%, with the European cut-off of 4 ng/mL). This generates a large number of useless biopsies,
involving both risks for the patients and costs for the national healthcare systems. Consequently,
efforts were recently made to discover new biomarkers useful for PCa screening, including our
proposal of interpreting a multi-parametric urinary steroidal profile with multivariate statistics.
This approach has been expanded to investigate new alleged biomarkers by the application of
untargeted urinary metabolomics. Urine samples from 91 patients (43 affected by PCa; 48 by benign
hyperplasia) were deconjugated, extracted in both basic and acidic conditions, derivatized with
different reagents, and analyzed with different gas chromatographic columns. Three-dimensional
data were obtained from full-scan electron impact mass spectra. The PARADISe software, coupled
with NIST libraries, was employed for the computation of PARAFAC2 models, the extraction of
the significative components (alleged biomarkers), and the generation of a semiquantitative dataset.
After variables selection, a partial least squares–discriminant analysis classification model was
built, yielding promising performances. The selected biomarkers need further validation, possibly
involving, yet again, a targeted approach.
Keywords: untargeted metabolomics; PARAFAC2; alignment; gas chromatography–mass spectrometry
(GC–MS); prostate carcinoma
1. Introduction
Prostate cancer (PCa) is the most common non-skin cancer in men [1,2] and the second most
frequently diagnosed malignancy in males worldwide [3]. The first biomarker for PCa detection was
prostatic acid phosphatase (PAP), which was introduced in the 1930s [1]. In the 1980s, PAP was replaced
by prostate-specific antigen (PSA) [1,4], a secreted protein encoded by a prostate-specific gene and
member of the tissue kallikrein family [1], which is produced almost exclusively in the prostate [5,6].
After the introduction of PSA, more men were diagnosed with PCa, with the majority having the
early-stage, clinically indolent form of the disease. However, a large number of patients affected by
a benign pathology, such as inflammation or hyperplasia, exhibited abnormal PSA values, which
lead to the execution of useless biopsies and demonstrate the low specificity of this biomarker [1,6].
This phenomenon was generally designated as “overdiagnosis” or “overtreatment” [1,4,7,8].
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Considerable effort has been devoted to improving the PSA-test performance, including the
introduction of PSA density, PSA velocity (and doubling time), the dosage of free or complexed PSA,
and the quantitation of its isoforms [1,2]. A combination of these parameters yields the Prostate Health
Index (PHI) [3].
Meanwhile, intensive research has been devoted to the search for different biomarkers, mainly
by applying omics methods (e.g., genomics, proteomics, transcriptomics, and metabolomics) [1], and
several authors have reviewed the emerging biomarkers, among which the most prominent are the
urinary prostate cancer antigen 3 (PCA3) [1,3,5] and transmembrane protease, serine 2 (TMPRSS2-ERG)
(sometimes combined together) [1,3,5]. Alpha-methylacyl-CoA Racemase (AMACR) demonstrated
high sensitivities and specificities on prostate biopsy, but it is not suitable for non-invasive detection
in urine [1,5]. Increased diagnostic performances were obtained by the serum dosage of human
kallikrein-related peptidase 2 (KLK2) in combination with total and free PSA [5]. An evolution of
the application of kallikreins consists in a blood measurement of the four existing isoforms which,
combined with clinical information, allows the probability calculation of PCa incidence [3]. Significantly
increased levels of prostasomes were found in blood samples from patients with PCa [9], while elevated
levels of urinary sarcosine were found to be associated with aggressive forms of prostate cancer [1].
Studies conducted in the 1970s and 1980s highlighted the correlation between increased
urinary excretion of polyamines (i.e., spermine, spermidine, and putrescine) and several types
of cancer [10,11]. However, anomalous oxidative degradation reactions of these polyamines resulted in
low concentrations of these biomarkers in approximately 20% of the patients, leading to false-negative
prediction and consequently limiting their application as diagnostic biomarkers [10].
The correlation between altered steroidal biosynthesis and PCa is well known [12–14]. For this
reason, in a previous study, we carried out a targeted analysis of urine samples, addressed to a large
panel of androgens, including testosterone and its principal phase I metabolites. The multivariate
statistical interpretation of these steroid profiles produced satisfactory results in terms of sensitivity,
specificity, and area under the curve (AUC) [15].
In this study, the search for new urinary biomarkers was undertaken by using untargeted methods.
In perspective, emerging biomarkers could possibly be combined with the most discriminating steroid
biomarkers to improve their screening performances further, without altering the inherent simplicity
of the instrumental procedure. In fact, the ideal biomarker should be cheap to determine, non-invasive,
easily accessible, and quickly quantifiable [1,2]. Taking into account the abovementioned considerations,
gas chromatography–electron impact mass spectrometry (GC–EIMS) would give a more suitable
solution than the other commonly used analytical techniques to provide a three-dimensional pattern
for untargeted analysis. Urine was chosen as the election matrix, as it is easily available in large
volumes and involves non-invasive sampling.
2. Materials and Methods
2.1. Chemicals and Reagents
Tert-butyl methyl ether (TBME), ethyl acetate, dithioerythritol, ammonium iodide (NH4I),
N-Methyl-N-(trimethylsilyl)trifluoroacetamide (TMSTFA), and trifluoroacetic anhydride (TFAA) were
provided by Sigma-Aldrich (Milan, Italy). β-glucuronidase from Escherichia coli was purchased from
Roche Life Science (Indianapolis, IN, USA). Ultra-pure water was obtained using a Milli-Q® UF-Plus
apparatus (Millipore, Bedford, MA, USA).
2.2. Samples Collection
The subjects involved in this study were recruited in the ambulatory of the Department of Urology
at the San Luigi Hospital of Orbassano (TO, Italy), after approval of the protocol by the reference Ethical
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Committee (protocol number 0019267). A total of 91 subjects were enrolled, including 43 affected by
prostate carcinoma (PCa, confirmed by a positive biopsy) and 48 diagnosed with benign prostatic
hyperplasia (BPH, with a PSA lower than the European cut-off of 4 ng/mL or with a PSA above the
threshold but a negative biopsy result). In a previous study, the progressive modification of the urinary
steroidal profile with age was investigated [16]. From this study, we decided to enroll only individuals
older than 60 years, when the bias effect due to aging became negligible [16]. Moreover, since ethnicity
represents another important bias factor, only Caucasian individuals were recruited. Finally, diabetes,
other carcinoma, metabolic diseases, and therapies suspected to alter the urinary steroid profile (such as
steroid therapy) were considered as exclusion criteria.
Body mass index (BMI), alcohol consumption, medical therapy, digital rectal examination,
PSA value, and biopsy Gleason Score (GS) were recorded. In detail, the group’s mean age and standard
deviation was 70 ± 10 years for BPH and 70 ± 8 years for PCa. BMI was within the range of normality
for all individuals (between 18.5 and 25), and PSA was 3.8 ± 2.3 ng/mL for BPH and 11.0 ± 9.5 ng/mL
for PCa. The PCa class was distributed as low risk (GS = 3 + 3, 15 patients), middle risk (GS = 3 + 4
and 4 + 3, 21 patients), and high risk (GS = 4 + 4 and 4 + 5, seven patients).
2.3. Sample Treatment and GC–MS Analysis
Firstly, the protein components of the urinary samples were precipitated by centrifugation at
4000 rpm for 5 min. Two aliquots (A and B) of 5 mL each were taken from each sample. The urine pH
was adjusted between 6.8 and 7.4 by adding 2 mL of phosphate buffer and a few drops of NaOH 1M or
HCl 1M whenever necessary. Enzymatic hydrolysis of the glucuronide metabolites was conducted
with 100 µL of β-glucuronidase from Escherichia coli (equivalent to 83 enzymatic units) by heating it
in the oven for 1 h. After cooling to room temperature, the two aliquots were subjected to different
liquid–liquid extraction (LLE) with 5 mL of TBME each, at basic (pH ≥ 10) and acid (pH ≤ 1) conditions,
respectively, obtained by the introduction of some drops of NaOH 1M and HCl 1M. Both aliquots were
dried under a gentle nitrogen stream at room temperature. The dried aliquot A was derivatized using
50 µL TFAA at 65 ◦C for 1 h. Then, the solvent was dried and the residue was dissolved in 50 µL TBME
and injected into the GC–MS. The chromatographic separation was achieved with a J&W Scientific
HP-5, 17 m × 0.2 mm (i.d.) × 0.33 µm (f.t.) capillary column. The oven temperature was programmed
as follows: The starting temperature of 90 ◦C was held for 1 min. Then, the temperature of 180 ◦C was
reached with a rate of 30 ◦C/min and held for 7 min. A final heating rate of 15 ◦C/min was applied until
the temperature of 325 ◦C was reached (held for 3 min). The chromatographic run lasted 22.20 min.
Aliquot B was derivatized using 50 µL of TMSTFA/NH4I/dithioerythritol (1.000:2:4 v/w/w), at 70 ◦C
for 30 min and then injected into a GC–MS equipped with a J&W Scientific HP-1, 17 m × 0.2 mm (i.d.) ×
0.11 µm (f.t.) capillary column. The oven temperature was programmed to heat up from 120 to 177 ◦C
at a rate of 70 ◦C/min, and from 177 to 236 ◦C at a rate of 5 ◦C/min. A final heating rate of 30 ◦C/min
was applied until the temperature of 315 ◦C was reached. The chromatographic run lasted 18.25 min.
Both the runs were performed in full-scan mode, in the interval 40–650 m/z at a scan rate of 2.28 scans/s.
Because the samples were analyzed in five analytical sections performed on different days,
it was important to monitor the occurrence of a data structure due to the different analytical sections.
The exploratory unsupervised data analysis can serve to this scope, and principal component analysis
(PCA) was employed. No clustering or trend related to the day of the analysis was detected.
2.4. Statistical Analysis
The main steps of the statistical analysis are reported in Figure 1.
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2.5. Pre-Treatmen of the Raw Data
The .AIA files of the chromatographic runs were d l a ed using the software ChemStation®.
The PARADISe version 3 software was employed to convert the files in a form suitable for
MATLAB (extension .mat). The alignment procedure, both propaedeutic and mandatory for the
following steps of data analysis, was executed over the three-way (samples × retention time × m/z)
array of size 91 × 3099 × 612 (over 172 million data) and 91 × 1640 × 652 (over 97 million data) for the
trifluoroacetyl (TFA) and trimethylsilyl (TMS) derivatives, respectively. The correlation optimized
warping (COW) was performed along the retention time and the m/z dimensions [17]. The two
matrices were seg ented along th retention time dimension to improve the performances of the
COW algorithm, and f r each slic the computation w s iterated u til a visually satisfying result was
obtained. Lastly, to improve the vis alization of the data, the baseline was subtracted. It is important
to highlight that the latter computational step only served to improve the data visualization by the
operator, because PARAFAC2 is able to recognize the baseline and the noise components, allowing
their automatic exclusion [18–21].
2.6. PARAFAC2 Models Computation and Molecular Identification
The aligned dataset was analyzed in the PARADISe software, to proceed with the computation of
PARAFAC2 models; the operating procedure consists in the manual identification of intervals along
the chromatogram (with each interval ideally containing approximately one peak). The PARAFAC2
models were built introducing the non-negativity constraint and performing 10,000 iterations for
interval [18–21].
Within the software, the operator can label the components as (i) baseline, (ii) noise, or (iii)
compounds. All the mass spectra of the components belonging to the third category are automatically
compared with the NIST database. A report is produced, including the relative concentrations of the
detected compounds (assuming a uniform response factor of 1), and the n (number subjectively chosen
by the user) most likely identifications for each compound. Finally, the relative concentrations were
normalized using the urinary creatinine values.
2.7. Classification Models
The dataset composed by the relative c ncentrations of th detected metabolit s for each sample
was used to perform partial least squares–discriminant analysis (PLS–DA) [22], classifying the samples
into having prostate carcinoma or not. Firstly, the dataset was log10 transformed (with the aim
of achieving a more even distribution of each of the variables) and autoscaled. Then, the variable
importance in projection (VIP) method (using a threshold of 1) [23] and genetic algorithms (GAs) [24]
were run to select the most relevant variables. The reduced dataset was finally used to build the
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PLS–DA classification model. The model was then validated using the repeated double cross-validation
(dCV) approach [25]. The PLS_Toolbox version 8.5 (Eigenvector Research, Inc., Manson, WA, USA)
was used to perform this part of the analysis [26].
3. Results and Discussion
The preliminary PARAFAC2 model extracted a total of 329 relevant compounds (184 from the
chromatographic run after TMS derivatization and 145 after TFA derivatization). Of these, 89 were
selected using the VIP algorithm, and a further 58 substances were discarded by one cycle of GAs.
The final dataset, consisting in a 91 × 32 (subjects × variables) matrix, was employed to build a PLS–DA
classification model. Due to the heterogeneity of the patients enrolled (in terms of pathology staging,
prostatic volume, and PSA values), the model was validated using repeated double cross-validation
(30 repetitions were performed) [25] instead of the standard external validation, in which the use of a
limited and heterogeneous population may result in significant bias. The plot reporting the Y-value
predicted in cross-validation (CV) in one of the several classification models produced during the
repeated double cross-validation process is shown in Figure 2A. The corresponding receiver operating
characteristic (ROC) curve is depicted in Figure 2B. The high values of the area under the curve (AUC)
for both the estimated and cross-validated ROCs are an indicator of high performances and robustness
of the model. In detail, using a discriminating Y-value of 0.5, the model provides 92.5 ± 2.2% sensitivity
and 88.7 ± 3.9% specificity for the cancer-affected population. On average, misclassification occurred
on about 3 ± 2 patients affected by carcinoma out of 43 and 5 ± 2 patients with hyperplasia out of 48.
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a rough semiquantitative report based on the total ion current (TIC) without any external calibration, 
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Figure 2. Y-value predicted in cross-validation (CV) (A) and receiver operating characteristic (ROC) curves
(B) of one of the several classification models built during the repeated double cross-validation procedure.
Of the 32 compounds selected by the dedicated algorithms to build the model, 17 were not found in
the available NIST libraries, while for seven other compounds, the identification provided by automatic
spectral matching was deemed incorrect. On the other hand, manual mass spectra interpretation
was made difficult by the structural similarity of many candidate biomarkers, as well as the effect of
the derivatizations, that introduced functional groups (e.g., −Si(CH3)3) yielding prevalent fragment
ions in the spect um. The mass spectra of he 32 metabolit s are provided as Supplementary Materials
(Supplement ry Figure S1). Table 1 r ports th eight id ntified compounds, ac om an ed by th ir Human
Metabolome Database (HMDB) a d Kyoto Encyclopedia of Genes and Genomes (KEGG) i entification
numbers, when available. Since the PARADISe output provides only a rough semiquantitative report
based on the total ion current (TIC) without any external calibration, the real physiological concentration
of each metabolite could not be evaluated. However, these absolute TIC values can be evaluated in
relative terms to provide an averaged qualitative comparison between the two populations for all the
analytes. The overexpression and underexpression of these metabolites allegedly linked to the occurrence
of PCa are reported in Table 1.
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Table 1. List of the 32 selected metabolites. The kind of derivatization, retention time, and expression in prostate cancer (PCa)-affected individuals are reported.
Moreover, metabolites with a putative identification are accompanied by the match score with NIST library and the relative identification (ID) number in the Human
Metabolome Database (HMDB) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. The mass spectra of the 32 metabolites are reported in
Supplementary Materials—Figure S1.
Compound Derivatization RetentionTime (min)
Match with
NIST HMDB ID KEGG ID
Expression in
PCa Patients
TMS
derivatives
1 5-Hydroxyindoleacetic acid TMS 5.26 893 HMDB0000763 C05635 overexpression
2 Unknown 1 TMS 5.86 - - - overexpression
3 Unknown 2 TMS 7.44 - - - underexpression
4 Androsterone TMS 8.14 912 HMDB0000031 C00523 overexpression
5 16-Hydroxydehydroisoandrosterone TMS 9.23 888 HMDB0000352 C05139 overexpression
6 Unknown 3 TMS 9.84 - - - comparable
7 Unknown 4 TMS 10.31 - - - underexpression
8 Unknown 5 TMS 10.61 - - - underexpression
9 Unknown 6 TMS 11.29 - - - underexpression
10 Unknown 7 TMS 11.32 - - - comparable
11 Enterodiol TMS 12.19 826 HMDB0005056 C18166 underexpression
12 5β-pregnanediol TMS 12.53 853 HMDB0005943 Not available underexpression
13 Unknown 8 TMS 13.6 - - - overexpression
14 Unknown 9 TMS 13.67 - - - comparable
15 Pregnanetriol TMS 13.73 904 HMDB0006070 Not available underexpression
16 Unknown 10 TMS 14.03 - - - underexpression
17 Unknown 11 TMS 14.50 - - - underexpression
18 Unknown 12 TMS 14.53 - - - underexpression
19 Unknown 13 TMS 14.6 - - - overexpression
20 Unknown 14 TMS 14.66 - - - underexpression
21 Unknown 15 TMS 15.04 - - - underexpression
TFA derivatives
22 Unknown 16 TFA 1.63 - - - underexpression
23 Unknown 17 TFA 1.71 - - - comparable
24 Vanillyl alcohol TFA 3.37 860 HMDB0032012 C06317 overexpression
25 Unknown 18 TFA 4.97 - - - comparable
26 Unknown 19 TFA 5.71 - - - underexpression
27 Unknown 20 TFA 3.32 - - - underexpression
28 Epiandrosterone TFA 15.61 925 HMDB0000365 C07635 comparable
29 Unknown 21 TFA 16.32 - - - underexpression
30 Unknown 22 TFA 17.87 - - - underexpression
31 Unknown 23 TFA 18.11 - - - overexpression
32 Unknown 24 TFA 18.24 - - - underexpression
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It is interesting to note that among the eight identified compounds, five (63%) are involved in steroidal
biosynthesis, confirming their potential in the detection and diagnosis of PCa. Similarly, Choi et al.
found elevated levels of 16-hydroxy-dehydroepiandrosterone, epiandrosterone, etiocholanolone, and
pregnanetriol in patients diagnosed with papillary thyroid carcinoma [27]. The first steroid appears to
also be overexpressed in the present case for patients with PCa, but pregnanetriol was underexpressed in
the same patients and epiandrosterone was found in comparable concentrations in the two populations.
Dehydroepiandrosterone is involved in the expression of insulin-like growth factor 1, whose dysregulation
is implicated in certain colon, liver, prostate, and breast cancers [28]. This observation may justify the
inclusion of 16-hydroxy-dehydroepiandrosterone among the potential biomarkers for PCa. Pregnanetriol,
together with 5 β-pregnanediol, is also known to be dysregulated in adrenal syndromes, such as
adrenal tumors or Cushing’s syndrome [29,30]. Increased androsterone levels were found in a cohort
of PCa-affected individuals within a multivariate investigation of the urinary steroidal profile, and the
present findings are in accordance with our previous study [16]. Other steroids that proved useful to
discriminate PCa from BPH [27] were possibly overlooked in the present untargeted selection because of
their low concentration in urine.
The overexpression of serotonin and its biomarkers (among which, 5-hydroxyindoleacetic acid)
represents a potential urinary biomarker for neuroblastic and carcinoid tumors [31]. While there is no
evidence in the literature of an association between 5-hydroxyindoleacetic acid and PCa, the present data
suggest such a hypothesis, as its overexpression is clearly evident in the PCa-affected population considered.
Phytoestrogens are a class of substances accredited to prevent the onset of cancer [32,33].
In accordance with this hypothesis, enterodiol is underexpressed in the present PCa population.
Among the 32 selected biomarkers, different contributions to the overall discrimination achieved
by the PLS–DA model (Figure 1) were expected. A rough estimation of the relative importance of
these biomarkers is expressed by their selectivity ratios [34], reported in Figure 3. Nine biomarkers
exhibit selectivity ratios higher that 0.1, while, for five others, values between 0.07 and 0.1 were found.
Interestingly, out of the nine biomarkers with the highest selectivity ratio, eight are underexpressed
in the PCa patients, apparently suggesting them as protective substances. The expression of the
14 metabolites is represented in the form of boxplots in Figure 4. Tentative PLS–DA models were
built with only these 9 and 14 biomarkers, but their overall efficiency significantly dropped with
respect to the model of 32 biomarkers, demonstrating that the relative contribution of the remaining
biomarkers is not negligible. In particular, the specificity index was considerably reduced in the models
of 9 biomarkers and 14 biomarkers, while the sensitivity score remained relatively high.
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reported in green, and the ones between the thresholds 0.07–0.1 are reported in red.
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Figure 4. Boxplot, in logarith ic (base-10) scale, of the 14 compounds above the selectivity ratio
threshold of 0.07 (se Figure 3).
Further testing was also conducted on the six biomarke s showing comparable m an intensity for
the two populations. O e variable at a time was removed, and a new classification model was computed
using a simple cros -validati n with each reduc d dataset. Five of the seven n w models yielded
decreased sensitivity a d specificity, while the other two m dels provided com arabl performance,
substanti lly confirming the choice of the 32 biomarker model.
4. Conclusions
The preliminary results reported in the present study support the premise that GC–MS
tridimensional data can be profitably exploited in untargeted metabolomics studies devoted to
prostatic carcinoma diagnosis. Compared to the more resource-demanding ultra-high-performance
liquid chromatography–tandem mass spectrometer (UHPLC–MS/MS) and ultra-high-performance
liquid chromatography–high-resolution mass spectrometry (UHPLC–HRMS) approaches frequently
presented in the literature, GC–MS offers comparable chromatographic resolution and structured
spectroscopic information, as is generated by the fragment ion pattern typical of electron impact
ionization. On these co plex data arrays, the ulti ate perfor ance in the extraction of crucial
information relies on the software purposely adopted and PARAFAC2 combined with VIP and GA
methods of variables selection proved to produce highly efficient models of class discrimination,
allowing us to distinguish prostatic carcinoma from benign hyperplasia with good sensitivity and
specificity scores.
A common limitation of untargeted metabolomics methods, including the present one, is that the
most abundant components of the screened samples are preferentially isolated as potential biomarkers
with respect to minor constituents, possibly present at trace levels. This explains the differences in
the selected biomarkers with respect to the targeted approach that we previously tested [27]. On the
other hand, complementary sets of biomarkers are extracted and then evaluated from targeted and
untargeted approaches, to be subsequently combined to achieve optimal performance. More work has
to be done on large populations of PCa-affected patients and controls to confirm the present findings,
and further effort is necessary to reveal the identity of the most valuable biomarkers and possibly
confirm their real value as interesting biomarkers by univariate statistics. Despite these limitations
to be overcome in the subsequent investigations, the strategy adopted in the present study, based on
Molecules 2019, 24, 3063 9 of 10
non-invasive urine sampling, cheap instrumentation, and advanced data treatment by PARADISe
software, appears to be extremely promising in PCa screening.
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